Sugammadex + neostigmine
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Anesthesia, General
Conditions
Anesthesia, General
Trial Timeline
Nov 10, 2005 โ Aug 29, 2006
NCT ID
NCT00451100About Sugammadex + neostigmine
Sugammadex + neostigmine is a phase 3 stage product being developed by Merck for Anesthesia, General. The current trial status is completed. This product is registered under clinical trial identifier NCT00451100. Target conditions include Anesthesia, General.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04546672 | Approved | Completed |
| NCT03276026 | Approved | Terminated |
| NCT03112993 | Approved | Completed |
| NCT02861131 | Approved | Completed |
| NCT02909439 | Approved | Completed |
| NCT01050543 | Phase 3 | Completed |
| NCT00825812 | Phase 3 | Completed |
| NCT00451217 | Phase 3 | Completed |
| NCT00451100 | Phase 3 | Completed |
Competing Products
20 competing products in Anesthesia, General